Semaglutide acetate 

Semaglutide acetate is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer^{[1][2][3][4][5]}.

1. 抗 Aβ_25-35 损伤实验：
Semaglutide acetate (1-100 nM；24 h) 显著提高 SH-SY5Y 细胞的存活率，增加 LC3II、Atg7、Beclin-1 和 P62 等自噬相关蛋白表达，抑制 Bax 并上调 Bcl-2，通过增强自噬、抑制凋亡并保护神经细胞^[1][2]。
2. 口腔鳞状细胞癌 (OSCC) 细胞实验：
Semaglutide acetate (5-40 μM；48 h) 剂量依赖性抑制 Cal27 和 HSC4 细胞的增殖、迁移及侵袭，上调 E-cadherin 并下调 Vimentin，激活 P38 MAPK 信号通路 (p-P38 表达增加)，诱导细胞凋亡^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

口腔鳞状细胞癌 (OSCC) 移植瘤模型
Semaglutide (3 μmol/kg；皮下注射；每周 3 次；3 周) acetate 显著抑制裸鼠口腔鳞状细胞癌 (OSCC) 移植瘤模型的肿瘤体积增长，下调增殖标志物 Ki67 和 PCNA，上调促凋亡蛋白 Bax 并下调抗凋亡蛋白 Bcl-xL，通过激活 P38 MAPK 通路诱导肿瘤细胞凋亡^[3]。
慢性 MPTP 诱导的帕金森病模型
Semaglutide (25 nmol/kg；腹腔注射；每 2 天 1 次；30 天) acetate 改善小鼠慢性 MPTP 诱导的帕金森病模型及其运动功能障碍，增加黑质酪氨酸 (TH) 阳性神经元数量，减少 α-突触核蛋白聚集及胶质细胞活化，降低氧化应激标志物 4-HNE 水平^[4]。
代谢功能障碍相关脂肪性肝病 (MASLD) 模型
Semaglutide (25 μg/kg/周+100 μg/kg/周；皮下注射；每周 1 次；11 周) acetate 在小鼠代谢功能障碍相关脂肪性肝病 (MASLD) 模型中，降低小鼠体重、血糖及血清肝酶 (ALT、AST、AP)，减少肝内甘油三酯沉积，改善肝脂肪变性及肝细胞气球样变，下调从头脂肪生成标志物 Acaca 和 Scd1^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1997361-85-9

固体

White to off-white

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Chang YF, et al. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci. 2020 Nov;81:234-239.  [Content Brief]

  [2]. Liu DX, et al. Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress. Parkinsons Dis. 2022 Jul 13;2022:6813017.  [Content Brief]

  [3]. Wang C, et al. Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. J Cancer Res Clin Oncol. 2025 Mar 7;151(3):103.  [Content Brief]

  [4]. Zhang L, et al. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9(1):157-171.  [Content Brief]

  [5]. Soto-Catalán M, et al. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Int J Mol Sci. 2024 Mar 4;25(5):2961.  [Content Brief]